Merrion H1 profits down despite revenue increase
ISEQ-quoted Merrion Pharmaceuticals today reported a net loss of €2.3m for the six months to end June, compared to a loss of €2.1m for H1 2008.
The decrease came despite a 378% increase in revenues to €1.7m from €354,000 in the same period of the previous year.